A Proof of Concept Study of Non-DNA Damaging DNMT1 Depletion Therapy for Myelodysplastic Syndrome.
Phase of Trial: Phase I/II
Latest Information Update: 25 Feb 2013
At a glance
- Drugs Decitabine (Primary)
- Indications Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Focus Pharmacogenomic; Therapeutic Use
- 01 Aug 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 05 Oct 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 11 Mar 2011 Status changed from suspended to recruiting as reported by ClinicalTrials.gov.